Indeed blocking RANKL by soluble RANK [31], [32], [33] or by the decoy receptor Osteoprotegerin [11], [34], [35], [36], [37] was proven to be effective in several in vivo models of bone tumors and leads to the clinical development of a fully-humanized monoclonal antibody directed against RANKL (Denosumab) [38]. This evidence concerns the gene TNFRSF11A and bone neoplasm.